Preliminary evaluation of technetium-99m-labeled ceftriaxone: Infection imaging agent for the clinical diagnosis of orthopedic infection

International Journal of Infectious Diseases

Volumn 17, Issue 4, 2013, Pages

  Kaul, Ankur ^a   Hazari, Puja P ^a   Rawat, Harish ^a   Singh, Baljinder ^b   Kalawat, Tek C ^c   Sharma, Sarika ^b   Babbar, Anil K ^a   Mishra, Anil K ^a  

^a INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^c SRI VENKATESWARA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Ceftriaxone; Infection imaging; SPECT; Technetium 99m

Indexed keywords

CEFTRIAXONE; TECHNETIUM 99M;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL INFECTION; BINDING ASSAY; BONE INFECTION; BONE SCINTISCANNING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG PURITY; DRUG STABILITY; FEMALE; HUMAN; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; PROTEIN BINDING; RABBIT; RADIOACTIVITY; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BONE DISEASES, INFECTIOUS; CEFTRIAXONE; DIAGNOSTIC IMAGING; DOGS; HUMANS; MICE; MODELS, ANIMAL; SENSITIVITY AND SPECIFICITY; TECHNETIUM;

EID: 84875367091     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2012.10.011     Document Type: Article

References (34)

1. Gemmel F., Dumarey N., Welling M. Future diagnostic agents. Semin Nucl Med 2009, 39:11-26.
2. Otto C.B., Huub R., Wim J.G., Corstens F.M. Radiopharmaceuticals to image infection and inflammation. Semin Nucl Med 2001, 31:288-295.
3. Lucignani G. The many roads to infection imaging. Eur J Nucl Med Mol Imaging 2007, 34:1873-1877.
4. Saha G.B. The fundamentals of nuclear pharmacy 2004, Springer, New York. Fifth ed.
5. Lupetti A., Welling M.M., Pauwels E.K., Nibbering P.H. Radiolabeled antimicrobial peptides for infection detection. Lancet Infect Dis 2007, 3:223-229.
6. Palestro C.J. In vivo leukocyte labeling. The quest continues. J Nucl Med 2007, 48:332-334.
7. Hnatowich D.J. Antibody radiolabeling. Problems and promises. Nucl Med Biol 1990, 17:49-55.
8. Langer O., Brunner M., Zeitlinger M., Ziegler S., Müller U., Dobrozemsky G., et al. In vitro and in vivo evaluation of 18F-ciprofloxacin for the imaging of bacterial infections with PET. Eur J Nucl Med Mol Imaging 2005, 32:143-150.
9. Singh A.K., Verma J., Bhatnagar A., Ali A. Tc-99m-labelled sparfloxacin: a specific infection imaging agent. World J Nucl Med 2003, 2:103-109.
10. Martin-Comin J., Soroa V., Rabiller G., Galli R., Cuesta L., Roca M., et al. [Diagnosis of bone infection with 99mTc-ceftizoxime]. Rev Esp Med Nucl 2004, 23:357.
11. 18F-labeled fleroxacin in rabbits with Escherichia coli infections studied with positron emission tomography. Antimicrob Agents Chemother 1992, 36:2286-2292.
12. Singh A.K., Verma J., Bhatnagar A., Sen S., Bose M. Tc-99m isoniazid: a specific agent for diagnosis of tuberculosis. World J Nucl Med 2003, 2:292-305.
13. Causse J.E., Pasqualini R., Cypriani B., Weil R., Van der Valk R., Bally P., et al. Labeling of ethambutol with 99mTc using a new reduction procedure. Pharmacokinetic study in the mouse and rat. Int J Rad Appl Instrum A 1990, 41:493-496.
14. Solanki K.K., Bomanji J., Siraj Q. 99mTc-Infecton: a new class of radiopharmaceutical for imaging infection. J Nucl Med 1993, 34:119.
15. Britton K.E., Vinjamuri S., Hall A.V., Solanki K., Siraj Q.H., Bomanji J., et al. Clinical evaluation of technetium-99m Infecton for the localisation of bacterial infection. Eur J Nucl Med 1997, 24:553-556.
16. Pauwels E.K., Welling M.M., Lupetti A., Nibbering P.H. Concerns about 99mTc-labelled ciprofloxacin for infection detection-reply. Eur J Nucl Med 2001, 28:781.
17. Signore A., D'Alessandria C., Lazzeri E., Dierck R. Can we produce an image of bacteria with radiopharmaceuticals?. Eur J Nucl Med Mol Imaging 2008, 35:1051-1055.
18. Martin C. Antimicrobial prophylaxis in surgery: general concepts and clinical guidelines. Infect Control Hosp Epidemiol 1994, 15:463-471.
19. Lawrence L., Livornese J., Dorothy S., Brett G., Paul R., Jerome S. Use of antibacterial agents in renal failure. Infect Dis Clin North Am 2004, 18:551-579.
20. Corsten F.H., Van der Meer J.W. Chemotactic peptides: new locomotion for imaging of infection. J Nucl Med 1991, 32:491-494.
21. Dumarey N., Blocklet D., Appelboom T., Tant L., Schouten A. Infecton is not specific for bacterial osteo-articular infective pathology. Eur J Nucl Med Mol Imaging 2002, 29:530-535.
22. Sarda L., Saleh-Mghir A., Peker C., Meulemans A., Cremieux A.C., Guludec L.D. Evaluation of (99m)Tc-ciprofloxacin scintigraphy in a rabbit model of Staphylococcus aureus prosthetic joint infection. J Nucl Med 2002, 43:239-245.
23. Sarda L., Crémieux A., Lebellec Y., Meulemans A., Lebtahi R., Hayem G., et al. Inability of 99mTc-ciprofloxacin scintigraphy to discriminate between septic and sterile osteoarticular diseases. J Nucl Med 2003, 44:920-926.
24. Hazari P.P., Chuttani K., Nitin K., Rashi M., Sharma R., Singh B., et al. Synthesis and biological evaluation of isonicotinic acid hydrazide conjugated with diethylenetriaminepentaacetic acid for infection imaging. Open Nucl Med J 2009, 1:33-42.
25. Norden C.W., Fierer J., Bryant R.E. Chronic staphylococcal osteomyelitis: treatment with regimen containing rifampin. Rev Infect Dis 1983, 5(Suppl 3):S495-S498.
26. Palmer S.M., Kang S.L., Cappelletty D.M., Rybak M.J. Bactericidal killing activities of cefepime, ceftazidime, cefotaxime, and ceftriaxone against Staphylococcus aureus and beta-lactamase-producing strains of Enterobacter aerogenes and Klebsiella pneumoniae in an in vitro infection model. Antimicrob Agents Chemother 1995, 39:1764-1771.
27. Jurisson S.S., Lydon J.D. Potential technetium small molecule radiopharmaceuticals. Chem Rev 1999, 99:2205-2218.
28. Siaens R.H., Rennen H.J., Boerman O.C., Dierckx R., Slegers G. Synthesis and comparison of 99mTc-enrofloxacin and 99mTc-ciprofloxacin. J Nucl Med 2004, 45:2088-2094.
29. Wise R. The clinical relevance of protein binding and tissue concentrations in antimicrobial therapy. Clin Pharmacokinet 1986, 11:470-482.
30. Nieto M.J., Alovero F.L., Manzo R.H., Mazzieri M.R. Benzenesulfonamide analogs of fluoroquinolones. Antibacterial activity and QSAR studies. Eur J Med Chem 2005, 40:361-369.
31. Naito T., Abburaki S., Kamachi H. Synthesis and structure activity relationships of a new series of cephalosporins. BMY-28142 and related compounds. J Antibiotic (Tokyo) 1986, 39:1092-1107.
32. Larikka M.J., Ahonen A.K., Niemelä O., Junila J.A., Hämäläinen M.M., Britton K., et al. Comparison of 99mTc ciprofloxacin, 99mTc white blood cell and three-phase bone imaging in the diagnosis of hip prosthesis infections: improved diagnostic accuracy with extended imaging time. Nucl Med Commun 2002, 23:655-661.
33. Singh B., Babbar A.K., Sarika S., Kaul A., Bhattacharya A., Mittal B.R., et al. To evaluate the clinical efficacy of a single vial kit preparation of 99mTc-ceftriaxone (Scintibact) for the diagnosis of orthopedic infections-first results. J Nucl Med 2010, 51(Suppl 2):373.
34. Esposito S., Leone S., Bassetti M., Borrè S., Leoncini F., Meani E., et al. Bone Joint Infections Committee for the Italian Society of Infectious Tropical Diseases (SIMIT). Italian guidelines for the diagnosis and infectious disease management of osteomyelitis and prosthetic joint infections in adults. Infection 2009, 37:478-496.